Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, a leader in synthetic biotechnology, will host its fourth virtual investor webinar on September 28, 2021, at 1:00 PM ET. The event, titled "Lab-to-Market, Delivering Disruptive Health and Beauty Products", will cover their biotechnology platform, consumer brands, and recent executive additions. Previous webinars, held on December 15, 2020, February 9, 2021, and April 22, 2021, are available for replay. Investors can join via live webcast or call.
Amyris, a leader in synthetic biotechnology (Nasdaq: AMRS), announced its participation in two investor conferences on September 13, 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature on-demand presentations starting at 7:00 AM ET, while the Cowen's 2nd Annual Health, Wellness & Beauty Summit will have live presentations at 2:10 PM ET. A webcast and replays will be available on the company's Investor Relations website. Amyris specializes in sustainable ingredients for health, beauty, and flavor markets.
Amyris announced the closing of its acquisition of Beauty Labs International Ltd. on August 31, enhancing its position in the clean beauty market. The acquisition integrates AI technology to improve customer experiences through personalized cosmetic recommendations. This strategic move aims to boost ecommerce revenue across Amyris brands, leveraging data science for better consumer engagement. CEO John Melo emphasized that Amyris is achieving significant revenue growth compared to peers. The integration of Beauty Labs technology is already showing promising early results, indicating potential for further growth.
Amyris, Inc. (Nasdaq: AMRS) announced the closing of acquisitions of OLIKA, Inc. and MG Empower Ltd. on August 11. OLIKA is known for its clean consumer products, particularly hydrating hand sanitizers, recently expanding its retail presence. MG Empower, a digital marketing agency, partners with global brands to drive influencer marketing innovations. CEO John Melo expressed optimism about these acquisitions, indicating they will generate new revenue and enhance growth capabilities for Amyris.
Amyris, Inc. (Nasdaq: AMRS) has launched Rose Inc., a clean color cosmetics brand created in collaboration with Rosie Huntington-Whiteley. The first collection, Modern Essentials, features products that are vegan, cruelty-free, and made with sustainable ingredients like Squalane. Registration for exclusive sales opens on August 24, 2021, with a global launch on August 27, 2021. Amyris aims to set a new standard in ethical and effective beauty products, leveraging its biotechnology platform to enhance product performance and sustainability.
Amyris, Inc. (Nasdaq: AMRS) announced positive in-vivo results for its licensed RNA vaccine, developed with the Infectious Disease Research Institute (IDRI). The study demonstrated that intranasal delivery generates antibodies and provides upper respiratory protection against SARS-CoV-2, potentially enhancing immunity compared to existing vaccines. Targeted for underserved countries, this vaccine is expected to enter human trials in South Africa next year. The company continues to explore a nasal delivery system to improve accessibility and effectiveness against respiratory diseases.
Amyris, Inc. (Nasdaq: AMRS) launched Terasana™ Clinical, marking its entry into the clean skincare market. The first product, Clear + Control Healthy Skin Serum, targets dry skin and blemishes, showing a 92% reduction in blemishes in clinical trials. The serum combines Squalane and Cannabigerol (CBG), both sustainably sourced. The launch is part of a strategy to introduce three new brands this summer, projected to boost revenue significantly in the second half of the year. Terasana Clinical emphasizes clean, effective formulations and eco-friendly packaging.
Amyris, Inc. (Nasdaq: AMRS) announced the continuation of its virtual investor mini-series, themed "Delivering on the Promise of Synthetic Biology." The fourth webinar is scheduled for September 28, 2021, focusing on its innovative cannabigerol (CBG) ingredient. The company reports strong demand for its ingredients and is launching three new consumer brands this month. CEO John Melo highlighted the robust growth expected in the second half of the year driven by these new launches and accelerated sales from existing brands.
Amyris, a synthetic biotechnology firm, reported Q2 2021 financial results with total revenue of $52.3 million, a 74% increase YoY. Underlying revenue rose 41% to $42.3 million, marked by a 59% surge in consumer sales. The company achieved a GAAP net income of $15 million versus a loss of $104 million last year. Cash at quarter-end totaled $215 million. Despite increased cash operating expenses of 46%, adjusted EBITDA improved, signaling positive operational momentum. The firm anticipates revenue exceeding $400 million for the year and aims for $2 billion by 2025.
